Values as of: 2025-05-23
COMMON STOCK | Biotechnology |
Last Closing
USD 79Change
-1.00 (-1.25)%Market Cap
USD 27.89BVolume
50.00Analyst Target
N/AVerdict
Verdict
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; UCB0222 for the treatment of Parkinson's disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Company Website : https://www.ucb.com
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| CSJA:F | CSL LTD SPON.ADR 2 |
+0.50 (+0.73%) |
USD 67.81B |
| CSJ:F | CSL Limited |
-1.00 (-0.72%) |
USD 67.05B |
| RGO:F | Regeneron Pharmaceuticals Inc |
-20.40 (-3.80%) |
USD 58.84B |
| 1AEA:F | argenx SE |
-5.00 (-0.98%) |
USD 36.54B |
| DUL:F | Alnylam Pharmaceuticals Inc |
-3.40 (-1.33%) |
USD 35.18B |
| 1AE:F | Argen-X |
+1.80 (+0.35%) |
USD 34.68B |
| 49B:F | BeiGene Ltd. |
+0.26 (+1.62%) |
USD 26.89B |
| 49BA:F | BeiGene Ltd |
N/A |
USD 25.20B |
| 22UA:F | BioNTech SE |
-2.10 (-2.36%) |
USD 21.41B |
| RPD:F | ROYALTY PHARMA OA DL-0001 |
-0.78 (-2.69%) |
USD 16.36B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -16.40% | 49% | F | 26% | F | ||
| Dividend Return | 0.74% | 62% | D | 23% | F | ||
| Total Return | -15.67% | 50% | F | 26% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 25.40% | 76% | C+ | 81% | B- | ||
| Dividend Return | 1.11% | 30% | F | 10% | F | ||
| Total Return | 26.50% | 76% | C+ | 74% | C | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 44.82% | 89% | A- | 94% | A | ||
| Dividend Return | 45.47% | 89% | A- | 88% | B+ | ||
| Total Return | 0.64% | 33% | F | 20% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 53.35% | 37% | F | 22% | F | ||
| Risk Adjusted Return | 85.23% | 98% | N/A | 87% | B+ | ||
| Market Capitalization | 27.89B | 99% | N/A | 93% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
